Dallas, Texas 05/16/2014 (FINANCIALSTRENDS) –Amarin Corporation plc (ADR) (NASDAQ:AMRN)’s rating of “fair value” was reaffirmed by investment analysts at MKM Partners in a recently release research report and at present they have a price target of $1.50 on the company’s stock which is less from its earlier price target of $2.00.
Separately, few other equities research analysts have also commented on the stock of the company. Analysts at Aegis in a research note reiterated a ‘hold’ rating on the shares of the company. Other analysts at Citigroup Inc. in a research note downgraded shares of the company from a ‘buy’ rating to a ‘neutral’ rating. And finally analysts at Jefferies Group in a research note increased their price objective on the shares of the company from $3.00 to $3.50.
Out of twelve investment analysts, 11 analysts have rated the stock with a ‘Hold’ rating, while one analyst has issued a ‘buy’ rating on the stock of the company. The stock has a consensus rating of ‘Hold’ and an average price objective of $4.18.
Earnings Highlights:
Amarin Corporation plc (ADR) (NASDAQ:AMRN) last released its quarterly earnings results on May 09, 2014. For the quarter the company reported earnings of $(0.16) per share, which is higher than consensus estimate of analysts of $(0.18) by $0.02. For the quarter the company reported revenue of $11 million as compared to the consensus estimate of $11.65 million. The revenue of the company was increased by 378.3% as compared to the comparative period of last year. Analysts expects that the company will post $(0.58) EPS for the recent financial year.
Company Brief:
A late-stage biopharmaceutical company, Amarin Corporation plc (ADR) (NASDAQ:AMRN)’s main focus is on the treatment of cardiovascular disease. The company is having expertise in lipid science. Yesterday, the stock of the company closed at $1.37, losing around 9.87% from its previous close.